Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
Philippe Huot, Susan H Fox, Jonathan M Brotchi. Monoamine reuptake inhibitors in Parkinson's disease. Parkinson's disease. vol 2015. 2015-03-26. PMID:25810948. |
despite wide discrepancy in the methodology of the studies reviewed, the following conclusions can be drawn: (1) selective serotonin transporter (sert), selective noradrenaline transporter (net), and dual sert/net inhibitors are effective against pd depression; (2) selective dopamine transporter (dat) and dual dat/net inhibitors exert an anti-parkinsonian effect when administered as monotherapy but do not enhance the anti-parkinsonian actions of l-3,4-dihydroxyphenylalanine (l-dopa); (3) dual dat/sert inhibitors might enhance the anti-parkinsonian actions of l-dopa without worsening dyskinesia; (4) triple dat/net/sert inhibitors might exert an anti-parkinsonian action as monotherapy and might enhance the anti-parkinsonian effects of l-dopa, though at the expense of worsening dyskinesia. |
2015-03-26 |
2023-08-13 |
Not clear |
Philippe Huot, Tom H Johnston, Katie D Lewis, James B Koprich, M Gabriela Reyes, Susan H Fox, Matthew J Piggott, Jonathan M Brotchi. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology. vol 82. 2015-01-09. PMID:24447715. |
uwa-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-dopa anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the mptp-lesioned common marmoset. |
2015-01-09 |
2023-08-12 |
marmoset |
Wai Kin D Ko, Qin Li, Erwan Bezar. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease. Neuroscience letters. vol 566. 2014-11-11. PMID:24572591. |
in animal models of parkinson's disease (pd), the serotonergic (5-hydroxytryptamine, 5-ht) system is thought to play an important pathophysiological role in the development and expression of l-3,4-dihydroxyphenylalanine (l-3,4-dihydroxyphenylalanine-dopa)-induced dyskinesia (lid). |
2014-11-11 |
2023-08-12 |
monkey |
Wai Kin D Ko, Qin Li, Erwan Bezar. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease. Neuroscience letters. vol 566. 2014-11-11. PMID:24572591. |
these behavioural data further support the role of the serotonergic system in expression of lid, highlighting the difficult challenge of targeting 5-ht neurons for alleviating dyskinesia and maintaining the therapeutic response of l-dopa. |
2014-11-11 |
2023-08-12 |
monkey |
N Nevalainen, S Af Bjerkén, G A Gerhardt, I Strömber. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia. Neuroscience. vol 260. 2014-09-25. PMID:24361918. |
nevertheless, knowledge of l-dopa-induced events that could lead to development of dyskinesias are limited and therefore the present work has evaluated (i) the role of the 5-ht system in l-dopa-derived dopamine synthesis when dopamine neurons are present, (ii) l-dopa-induced effects on striatal dopamine release and clearance, and on 5-ht nerve fiber density, and (iii) the behavioral outcome of altered 5-ht transmission in dyskinetic rats. |
2014-09-25 |
2023-08-12 |
rat |
Melissa M Conti, Corinne Y Ostock, David Lindenbach, Adam A Goldenberg, Elias Kampton, Rich Dell'isola, Aaron C Katzman, Christopher Bisho. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology. vol 77. 2014-08-26. PMID:24067924. |
effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-dopa-induced dyskinesia in hemi-parkinsonian rats. |
2014-08-26 |
2023-08-12 |
human |
Erwan Bézard, Ana Muñoz, Elisabetta Tronci, Elsa Y Pioli, Qin Li, Gregory Porras, Anders Björklund, Manolo Cart. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia. Neuroscience research. vol 77. issue 4. 2014-08-01. PMID:24135129. |
accordingly, drugs able to dampen the activity of serotonin neurons can suppress l-dopa-induced dyskinesia in animal models of parkinson's disease. |
2014-08-01 |
2023-08-12 |
rat |
Erwan Bezard, Elisabetta Tronci, Elsa Y Pioli, Qin Li, Gregory Porras, Anders Björklund, Manolo Cart. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Movement disorders : official journal of the Movement Disorder Society. vol 28. issue 8. 2014-03-06. PMID:23389842. |
the serotonin (5-hydroxytryptamine [5ht]) system has recently emerged as an important player in the appearance of l-3,4-dihydroxyphenylalanine (levodopa [l-dopa])-induced dyskinesia in animal models of parkinson's disease. |
2014-03-06 |
2023-08-12 |
rat |
Erwan Bezard, Elisabetta Tronci, Elsa Y Pioli, Qin Li, Gregory Porras, Anders Björklund, Manolo Cart. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Movement disorders : official journal of the Movement Disorder Society. vol 28. issue 8. 2014-03-06. PMID:23389842. |
thus, drugs able to dampen the activity of serotonin neurons hold promise for the treatment of dyskinesia. |
2014-03-06 |
2023-08-12 |
rat |
Erwan Bezard, Elisabetta Tronci, Elsa Y Pioli, Qin Li, Gregory Porras, Anders Björklund, Manolo Cart. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Movement disorders : official journal of the Movement Disorder Society. vol 28. issue 8. 2014-03-06. PMID:23389842. |
the authors investigated the ability of the mixed 5-ht 1a/1b receptor agonist eltoprazine to counteract l-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned rats and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp)-treated macaques. |
2014-03-06 |
2023-08-12 |
rat |
Golnasim Riahi, Marc Morissette, Pershia Samadi, Martin Parent, Thérèse Di Paol. Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia. Biochemical pharmacology. vol 86. issue 7. 2013-12-17. PMID:23954709. |
basal ganglia serotonin 1b receptors in parkinsonian monkeys with l-dopa-induced dyskinesia. |
2013-12-17 |
2023-08-12 |
monkey |
Alexander Prinz, Lisa-Marie Selesnew, Birgit Liss, Jochen Roeper, Thomas Carlsso. Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease. Experimental neurology. vol 248. 2013-11-27. PMID:23810738. |
this lesion- and treatment-induced plasticity of the serotonin might contribute to its role in l-dopa induced dyskinesia. |
2013-11-27 |
2023-08-12 |
mouse |
Meaghan C Creed, José N Nobreg. The role of serotonin in the antidyskinetic effects of deep brain stimulation: focus on antipsychotic-induced motor symptoms. Reviews in the neurosciences. vol 24. issue 2. 2013-08-21. PMID:23399586. |
however, the current evidence suggests that 5-ht alterations do not play an important role in the effectiveness of dbs in models of dyskinesias induced by chronic apds. |
2013-08-21 |
2023-08-12 |
Not clear |
Abraham Lieberman, Narayanan Krishnamurth. Is there room for non-dopaminergic treatment in Parkinson disease? Journal of neural transmission (Vienna, Austria : 1996). vol 120. issue 2. 2013-07-19. PMID:23242741. |
droxidopa, a drug that increases norepinephrine, treats orthostatic hypotension, cholinomimetic drugs sometimes help with fog and difficulty with balance, pimavanserin, a drug that blocks serotonin receptors, treats paranoia and hallucinations, and anti-glutaminergic drugs treat dyskinesias. |
2013-07-19 |
2023-08-12 |
Not clear |
Saki Shimizu, Yukihiro Ohn. Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors. Aging and disease. vol 4. issue 1. 2013-02-21. PMID:23423244. |
thus, 5-ht(1a) agonists improve the various motor disorders associated with dopaminergic deficits, dyskinesia induced by chronic l-dopa treatment, mood disturbances (anxiety and depression) and dopamine agonist-induced emesis. |
2013-02-21 |
2023-08-12 |
Not clear |
Elisabetta Tronci, Eunju Shin, Anders Björklund, Manolo Cart. Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study. Neuroscience research. vol 73. issue 2. 2013-02-19. PMID:22450171. |
moreover, sert expression levels suggest that reduced striatal and pallidal serotonin innervation might have contributed to the lower dyskinesia levels observed in a subset of amphetamine-responsive rats. |
2013-02-19 |
2023-08-12 |
rat |
Joanna García, Thomas Carlsson, Máté Döbrössy, Guido Nikkhah, Christian Winkle. Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model. Brain research. vol 1470. 2013-01-15. PMID:22759908. |
impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat parkinson model. |
2013-01-15 |
2023-08-12 |
rat |
Joanna García, Thomas Carlsson, Máté Döbrössy, Guido Nikkhah, Christian Winkle. Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model. Brain research. vol 1470. 2013-01-15. PMID:22759908. |
serotonin neurons, included into the dopaminergic cell suspension due to the nature of the dissection process, have been suggested as a key factor for the development of gid, since the administration of the serotonin (5-ht)(1a)-receptor agonist buspirone reduced dyskinesia in transplanted pd patients. |
2013-01-15 |
2023-08-12 |
rat |
Christopher Bishop, Jessica A George, William Buchta, Adam A Goldenberg, Mohamed Mohamed, Sando O Dickinson, Satie Eissa, Karen L Eskow Jaunaraj. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. The European journal of neuroscience. vol 36. issue 6. 2013-01-09. PMID:22762478. |
serotonin transporter inhibition attenuates l-dopa-induced dyskinesia without compromising l-dopa efficacy in hemi-parkinsonian rats. |
2013-01-09 |
2023-08-12 |
rat |
Christopher Bishop, Jessica A George, William Buchta, Adam A Goldenberg, Mohamed Mohamed, Sando O Dickinson, Satie Eissa, Karen L Eskow Jaunaraj. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. The European journal of neuroscience. vol 36. issue 6. 2013-01-09. PMID:22762478. |
growing evidence suggests that, following dopamine cell loss, serotonin neurons acting as surrogates for dopaminergic processes take up l-dopa, convert it to dopamine and release it in an unregulated fashion that precipitates dyskinesia. |
2013-01-09 |
2023-08-12 |
rat |